Pharmaceutical Sales and Marketing Articles

Make a Match

Eli Lilly's August 2008 announcement that it will transfer not only its clinical trial monitoring function to Quintiles, but also its early drug development facility to Covance, sent tremors through industry R&D. That transaction, and others like it, signals a profound shift in outsourcing practices.

Author(s): 
David Zuckerman , Rachael Zuckerman , Kenneth Getz , Charles Piper
Journal: 
Pharmaceutical Executive, Apr 1, 2009

Deborah Dunsire: Woman of the Year

A handful of times in the span of a human life, there come moments that illuminate how the world could change. For some, it was Woodstock, or the resignation of Richard Nixon, or, more recently, the fall of the Berlin Wall.

Author(s): 
Joanna Breitstein
Journal: 
Pharmaceutical Executive, Apr 1, 2009

Through the Looking Glass

Soon after his swearing-in, President Barack Obama issued a memorandum to all federal agencies advocating greater transparency in government actions. Obama also called for high ethical standards for government officials, a stance that helped derail the confirmation of Tom Daschle as Secretary of Health and Human Services (HHS).

Author(s): 
Jill Wechsler
Journal: 
Pharmaceutical Executive, Mar 1, 2009

Through the Looking Glass

Soon after his swearing-in, President Barack Obama issued a memorandum to all federal agencies advocating greater transparency in government actions. Obama also called for high ethical standards for government officials, a stance that helped derail the confirmation of Tom Daschle as Secretary of Health and Human Services (HHS).

Author(s): 
Jill Wechsler
Journal: 
Pharmaceutical Executive, Mar 1, 2009

Learning From Fast-Action Obama

When President Obama took office January 20, he immediately adopted the policy I've recommended to new leaders for years: He hit the ground running. On Day One, he established new restrictions on lobbying, reversed a Bush-era policy that let agencies veil their documents, and froze salaries in the Executive Branch.

Author(s): 
Sander Flaum
Journal: 
Pharmaceutical Executive, Mar 1, 2009

Ad Stars 2009

This year's Ad Stars showcases 12 agencies behind some of industry's most captivating work. From fierce grizzly bears battling fungal infections to children's doodles erasing pink eye, this year's pharma marketing tools prove that drug ads can be smart, educational, and (even in these dark times) strike a smile.

Author(s): 
Brittany Agro, Assistant Editor
Journal: 
Pharmaceutical Executive, Mar 1, 2009

Attack of the Monster Merger

That question has been asked almost daily by Wall Street and the business media since late 2006, when then-new CEO Jeffrey B. Kindler announced the death of torcetrapib, the company's would-be savior. The No. 1 pharmaceutical company with the best-selling drug in history—and the steepest patent cliff—has come to symbolize the "crisis" of the drug industry and its bankrupt blockbuster model.

Author(s): 
Walter Armstrong
Journal: 
Pharmaceutical Executive, Mar 1, 2009

Fifth Annual Press Audit: Safety in the Spotlight

There may be fewer articles about the pharma industry these days—but the stories that do run are increasingly negative and one-sided.

Author(s): 
Stephen J. Porth , George P. Sillup
Journal: 
Pharmaceutical Executive, Mar 1, 2009

The New Sales Force

Performance on Overall Sales Experience

Author(s): 
Brittany Agro, Assistant Editor
Journal: 
Pharmaceutical Executive, Mar 1, 2009

Securing Savings

Everyone wants to reform the nation's healthcare system. The main problem is that the US healthcare bill keeps rising faster than the economy, with little to show in terms of higher quality of care.

Author(s): 
Jill Wechsler
Journal: 
Pharmaceutical Executive, Feb 1, 2009
Syndicate content